My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Inhibikase Therapeutics, Inc. - Common Stock (NQ:IKT)

1.760 +0.020 (+1.15%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Inhibikase Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Why Dermata Therapeutics Shares Are Trading Higher By Over 57%; Here Are 20 Stocks Moving Premarket ↗

January 05, 2024

Shares of Dermata Therapeutics, Inc. (NASDAQ: DRMA) rose sharply in pre-market trading after the company announced the issuance of a new patent in Japan for its DMT410 program for the treatment of...

Via Benzinga

Topics Intellectual Property

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

December 13, 2023

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

December 12, 2023

Via Benzinga

Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

December 11, 2023

Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the...

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

December 04, 2023

Via Benzinga

Inhibikase Therapeutics: Q3 Earnings Insights ↗

November 14, 2023

Via Benzinga

Earnings Preview For Inhibikase Therapeutics ↗

November 13, 2023

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 05, 2023

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 04, 2023

Via Benzinga

Earnings Preview: Inhibikase Therapeutics ↗

May 12, 2023

Via Benzinga

FDA Removes Regulatory Overhang From Inhibikase Therapeutics Parkinson/Atrophy Program ↗

March 08, 2023

Via Benzinga

Looking Into Inhibikase Therapeutics's Return On Capital Employed ↗

December 27, 2022

Via Benzinga

Why Cal-Maine Foods Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

October 04, 2023

Gainers Gaucho Group Holdings, Inc. (NASDAQ: VINO) jumped 95.2% to $3.7280. Gaucho Group is planning to list two of its retail properties in Argentina, in San Rafael and Cordoba, for sale, priced at $2...

Via Benzinga

Why Fresh Tracks Therapeutics Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket ↗

September 20, 2023

Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares rose 70.2% to $0.8937 in pre-market trading after falling 10% on Tuesday.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

September 19, 2023

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

August 25, 2023

Via Benzinga

Why Avalo Therapeutics Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket ↗

August 18, 2023

Gainers

Via Benzinga

Inhibikase Therapeutics: A Novel And Promising Approach To Neurodegeneration And Oncology ↗

May 24, 2023

IKT's heavily discounted valuation provides a compelling risk/reward given the ability to establish both safety and efficacy in Parkinson’s disease let alone any progress in oncology.

Via Talk Markets

Earnings Scheduled For August 14, 2023 ↗

August 14, 2023

Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2023 ↗

April 18, 2023

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

April 18, 2023

We're starting off the day with a look at the biggest pre-market stock movers traders will want to keep an eye on Tuesday!

Via InvestorPlace

Why RAPT Therapeutics Shares Are Trading Lower By Over 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

March 14, 2023

Gainers Ainos, Inc. (NASDAQ: AIMD) shares jumped 69.3% to $1.27 after the company announced it signed a Memorandum of Understanding with Merdury Biopharmaceutical to jointly explore and develop a...

Via Benzinga

Why Is Chevron (CVX) Stock Up Today? ↗

January 26, 2023

Chevron (CVX) stock is on the rise Thursday following a new share buyback program and dividend for investors, as well as upcoming earnings.

Via InvestorPlace

LUV Stock Alert: Southwest Reports $800 Million Loss During Holiday Mishap ↗

January 26, 2023

Southwest Airlines (LUV) stock is falling on Thursday following a massive $800 million hit to its net income in Q4 2022.

Via InvestorPlace

Why Panbela Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

January 26, 2023

Gainers MicroAlgo Inc. (NASDAQ: MLGO) shares jumped 74% to $2.90. MicroAlgo recently entered into securities purchase agreement for up to $3.2 million.

Via Benzinga

Why Is Inhibikase Therapeutics (IKT) Stock Down 11% Today? ↗

January 26, 2023

Inhibikase Therapeutics (IKT) stock is falling on Thursday after the company announced a registered direct offering and private placement.

Via InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

January 26, 2023

We're starting off the day with an overview of the biggest pre-market stock movers that traders need to watch on Thursday!

Via InvestorPlace

Why Grom Social Enterprises Shares Are Trading Lower By 30%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

January 25, 2023

Gainers Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) shares surged 85% to $2.2200. Sonoma Pharmaceuticals and EMC Pharma announced Department of Defense DAPA registration for Microcyn(R) Rx products.

Via Benzinga

Why Baudax Bio Shares Are Trading Higher By 60%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

January 24, 2023

Gainers Baudax Bio, Inc. (NASDAQ: BXRX) shares surged 59.7% to $5.03 after the company announced the outcome of its first interim analysis in a Phase II trial of BX1000 for neuromuscular blockade in...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 16, 2022 ↗

November 16, 2022

Upgrades

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.